NASDAQ:MDGL

Madrigal Pharmaceuticals Stock Forecast, Price & News

$78.26
-0.16 (-0.20 %)
(As of 09/21/2021 01:40 PM ET)
Add
Compare
Today's Range
$77.90
$79.70
50-Day Range
$78.35
$100.95
52-Week Range
$77.60
$142.62
Volume1,524 shs
Average Volume151,424 shs
Market Capitalization$1.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.11
30 days | 90 days | 365 days | Advanced Chart
Receive MDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Madrigal Pharmaceuticals logo

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.44 out of 5 stars

Medical Sector

150th out of 1,352 stocks

Pharmaceutical Preparations Industry

66th out of 665 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Madrigal Pharmaceuticals (NASDAQ:MDGL) Frequently Asked Questions

Is Madrigal Pharmaceuticals a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Madrigal Pharmaceuticals stock.
View analyst ratings for Madrigal Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Madrigal Pharmaceuticals?

Wall Street analysts have given Madrigal Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Madrigal Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Madrigal Pharmaceuticals' next earnings date?

Madrigal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Madrigal Pharmaceuticals
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($3.72) earnings per share for the quarter, missing analysts' consensus estimates of ($3.58) by $0.14.
View Madrigal Pharmaceuticals' earnings history
.

How has Madrigal Pharmaceuticals' stock been impacted by Coronavirus?

Madrigal Pharmaceuticals' stock was trading at $81.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDGL shares have decreased by 3.5% and is now trading at $78.26.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MDGL?

9 brokerages have issued 1 year price objectives for Madrigal Pharmaceuticals' shares. Their forecasts range from $111.00 to $204.00. On average, they expect Madrigal Pharmaceuticals' share price to reach $172.13 in the next year. This suggests a possible upside of 119.9% from the stock's current price.
View analysts' price targets for Madrigal Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Madrigal Pharmaceuticals' key executives?

Madrigal Pharmaceuticals' management team includes the following people:
  • Paul A. Friedman, Chairman, President & Chief Executive Officer
  • Alex G. Howarth, Chief Financial Officer
  • Rebecca A. Taub, Director & Chief Medical Officer
  • Brian J. Lynch, Senior Vice President & General Counsel
  • Remy Sukhija, Chief Commercial Officer & Senior Vice President

Who are some of Madrigal Pharmaceuticals' key competitors?

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.32%), BlackRock Inc. (5.49%), State Street Corp (3.75%), Armistice Capital LLC (3.57%), Artisan Partners Limited Partnership (1.33%) and Citigroup Inc. (1.20%). Company insiders that own Madrigal Pharmaceuticals stock include Bay City Capital Llc and Fred B Craves.
View institutional ownership trends for Madrigal Pharmaceuticals
.

Which institutional investors are selling Madrigal Pharmaceuticals stock?

MDGL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Deutsche Bank AG, BlackRock Inc., Schonfeld Strategic Advisors LLC, Capital Impact Advisors LLC, FMR LLC, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Madrigal Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Madrigal Pharmaceuticals stock?

MDGL stock was purchased by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Citigroup Inc., Marshall Wace LLP, Marshall Wace LLP, Marshall Wace North America L.P., L1 Capital Pty Ltd, Vanguard Group Inc., and Maven Securities LTD.
View insider buying and selling activity for Madrigal Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $78.26.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals has a market capitalization of $1.30 billion. The biopharmaceutical company earns $-202,240,000.00 in net income (profit) each year or ($13.09) on an earnings per share basis.

How many employees does Madrigal Pharmaceuticals have?

Madrigal Pharmaceuticals employs 42 workers across the globe.

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2011.

What is Madrigal Pharmaceuticals' official website?

The official website for Madrigal Pharmaceuticals is www.madrigalpharma.com.

Where are Madrigal Pharmaceuticals' headquarters?

Madrigal Pharmaceuticals is headquartered at 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The biopharmaceutical company can be reached via phone at (484) 380-9263 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.